煤矿中的金丝雀？初治患者中出现对所有整合酶链转移抑制剂耐药的传播性突变
Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient.
作者信息
McGee Kara S, Okeke Nwora Lance, Hurt Christopher B, McKellar Mehri S
机构信息
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
出版信息
Open Forum Infect Dis. 2018 Nov 8;5(11):ofy294. doi: 10.1093/ofid/ofy294. eCollection 2018 Nov.
Abstract
Transmitted drug resistance to the integrase strand transfer inhibitor (INSTI) class of antiretrovirals is very rare. We present a case of a treatment-naive female patient with human immunodeficiency virus harboring resistance to all INSTIs, including bictegravir and dolutegravir.
摘要
对整合酶链转移抑制剂（INSTI）类抗逆转录病毒药物产生的传播性耐药非常罕见。我们报告了一例初治女性人类免疫缺陷病毒患者，该患者对包括比克替拉韦和多替拉韦在内的所有INSTI均具有耐药性。
相似文献
1
Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient.煤矿中的金丝雀？初治患者中出现对所有整合酶链转移抑制剂耐药的传播性突变
Open Forum Infect Dis. 2018 Nov 8;5(11):ofy294. doi: 10.1093/ofid/ofy294. eCollection 2018 Nov.
2
Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis.2009年至2016年加拿大不列颠哥伦比亚省人类免疫缺陷病毒1型整合酶链转移抑制剂耐药性的流行情况：一项纵向分析。
Open Forum Infect Dis. 2019 Feb 12;6(3):ofz060. doi: 10.1093/ofid/ofz060. eCollection 2019 Mar.
3
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.初治和经治的HIV-1感染患者中整合酶链转移抑制剂耐药突变的流行情况：单中心经验
AIDS Res Hum Retroviruses. 2018 Jul;34(7):570-574. doi: 10.1089/AID.2018.0006. Epub 2018 May 9.
4
Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.整合酶链转移抑制剂治疗人类免疫缺陷病毒感染的综述。
Expert Rev Anti Infect Ther. 2015;13(10):1195-212. doi: 10.1586/14787210.2015.1075393. Epub 2015 Aug 9.
5
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.韩国初治和经治HIV患者中抗逆转录病毒治疗整合酶链转移抑制剂耐药突变情况
AIDS Res Hum Retroviruses. 2019 Feb;35(2):213-216. doi: 10.1089/AID.2018.0213. Epub 2018 Oct 23.
6
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.西班牙整合酶抑制剂传播耐药性监测：对临床实践的影响。
J Antimicrob Chemother. 2019 Jun 1;74(6):1693-1700. doi: 10.1093/jac/dkz067.
7
Primary resistance to integrase strand-transfer inhibitors in Europe.欧洲对整合酶链转移抑制剂的原发性耐药性。
J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.
8
Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.多替拉韦：一种用于治疗艾滋病病毒的新型整合酶链转移抑制剂。
Pharmacotherapy. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. Epub 2013 Dec 18.
9
Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.多替拉韦，一种用于治疗HIV-1感染的第二代整合酶抑制剂。
Ann Pharmacother. 2014 Mar;48(3):395-403. doi: 10.1177/1060028013513558. Epub 2013 Nov 19.
10
Transmitted Drug Resistance Against Integrase Strand Transfer Inhibitors in Iranian HIV-Infected Naïve Patients.伊朗初治HIV感染患者中针对整合酶链转移抑制剂的传播性耐药
Avicenna J Med Biotechnol. 2023 Jul-Sep;15(3):203-206. doi: 10.18502/ajmb.v15i3.12931.
引用本文的文献
1
Practical updates in clinical antiviral resistance testing.临床抗病毒耐药性检测的实用更新。
J Clin Microbiol. 2024 Aug 14;62(8):e0072823. doi: 10.1128/jcm.00728-23. Epub 2024 Jul 25.
2
High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients.比替拉韦和新型螺环β-内酰胺 BSS-730A 对 RAL 初治和 RAL 失败的 HIV-2 分离株的高瞬时抑制潜能。
Int J Mol Sci. 2022 Nov 18;23(22):14300. doi: 10.3390/ijms232214300.
3
Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.埃塞俄比亚 HIV-1 型 C 亚型感染患者的治疗前整合酶抑制剂耐药性和自然多态性。
Viruses. 2022 Mar 30;14(4):729. doi: 10.3390/v14040729.
4
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.博茨瓦纳接受基于整合酶链转移抑制剂方案治疗失败的重度治疗患者中的 HIV-1 亚型 C 耐药突变。
Viruses. 2021 Mar 31;13(4):594. doi: 10.3390/v13040594.
5
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.一线基于整合酶抑制剂的抗逆转录病毒治疗的病毒学失败和病毒抑制时间的预测因素。
Clin Infect Dis. 2021 Oct 5;73(7):e2134-e2141. doi: 10.1093/cid/ciaa1614.
6
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.整合酶抑制剂耐药突变的监测用于传播的 HIV-1 药物耐药性。
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.
7
Management of Virologic Failure and HIV Drug Resistance.病毒学失败和 HIV 耐药管理。
Infect Dis Clin North Am. 2019 Sep;33(3):707-742. doi: 10.1016/j.idc.2019.05.004. Epub 2019 Jun 27.
8
Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.在美国人类免疫缺陷病毒诊断中进行基因检测的临床影响和成本效益。
Clin Infect Dis. 2020 Mar 17;70(7):1353-1363. doi: 10.1093/cid/ciz372.
本文引用的文献
1
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.人类免疫缺陷病毒耐药性：美国国际抗病毒学会 2018 年推荐意见。
Clin Infect Dis. 2019 Jan 7;68(2):177-187. doi: 10.1093/cid/ciy463.
2
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.抗逆转录病毒药物治疗和预防成人 HIV 感染：美国国际抗病毒学会 2018 年推荐意见。
JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.
3
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.美国大型临床患者人群中传播的人类免疫缺陷病毒 1 型耐药的分子流行病学和遗传机制的趋势。
Clin Infect Dis. 2019 Jan 7;68(2):213-221. doi: 10.1093/cid/ciy453.
4
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.2000年至2009年美国初治HIV-1感染患者中含抗逆转录病毒治疗耐药相关突变的HIV-1流行率变化
AIDS Res Hum Retroviruses. 2018 Aug;34(8):672-679. doi: 10.1089/AID.2017.0295. Epub 2018 Jun 5.
5
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯复方片剂与多替拉韦加拉米夫定和丙酚替诺福韦二吡呋酯用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1490）：一项随机、双盲、多中心、3 期、非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
6
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1489）：一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
7
Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?我们是否应该在新诊断出人类免疫缺陷病毒的患者中检测基线整合酶耐药？
Clin Infect Dis. 2017 Oct 15;65(8):1274-1281. doi: 10.1093/cid/cix542.
8
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
9
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.在初治 HIV-1 感染的成人中，每日一次多替拉韦与达芦那韦/利托那韦比较（FLAMINGO）：随机、开放标签、3b 期研究的 48 周结果。
Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1.
10
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.多替拉韦用于既往接受抗逆转录病毒治疗且对拉替拉韦和/或埃替拉韦耐药的HIV-1患者：III期VIKING-3研究的24周结果
J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19.
Zotero 插件